

# 2019 Future of Vitiligo R&D Pipeline Drugs and Companies- Analysis of Global Vitiligo Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

<https://marketpublishers.com/r/2CD33C30E33EN.html>

Date: January 2019

Pages: 65

Price: US\$ 2,199.00 (Single User License)

ID: 2CD33C30E33EN

## Abstracts

The global demand for Vitiligo treatment options is emerging rapidly driven by consumption in major emerging markets. As more growth opportunities will turn up over the medium to long term future, a large number of companies are working on Vitiligo pipeline. Companies quickly adapting to the change and moving their products to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and inadequate financial support are holding some of the Vitiligo pipeline companies from advancing their products into Phase 3 or Phase 4.

### Vitiligo Report Description

The H1 2019 pipeline review report on Vitiligo pipeline is a comprehensive study on the candidates in development across different phases worldwide. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Vitiligo pipeline compounds.

The Vitiligo pipeline guide presents information on all active drugs currently being developed for Vitiligo. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Vitiligo

pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Vitiligo drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Vitiligo product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Vitiligo pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Vitiligo pipeline report includes

An overview of Vitiligo disease including symptoms, causes, diagnosis and available treatment options is provided.

Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc

Phase wise count of pipeline compounds

Company wise list of pipeline compounds

Mechanism of Action wise pipeline compounds

For each pipeline product, the following details are provided-

Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator,

Synonym, Orphan Drug Status, New Molecular Entity, Area)

Current status of development

Drug overview

Mechanism of Action

Pre-clinical and Clinical Trials

## **REASONS TO BUY**

The report is designed to help industry executives promote the success and continued growth of their organizations

Get clear understanding of the entire Vitiligo pipeline, with details on active projects

Stay ahead of the competition through comprehensive knowledge of Vitiligo pipeline progress

Get in detail information of each product with updated information on each project along with key milestones

Gain clear insights into the market through in-depth strategic analysis review

Know the list of companies participating in global Vitiligo pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

## Contents

### **1. TABLE OF CONTENTS**

- 1.1 List of Tables
- 1.2 List of Figures

### **2. GLOBAL VITILIGO PIPELINE OVERVIEW**

- 2.1 Key Findings, 2019
- 2.2 Disease Overview
- 2.3 Report Guide and Research Methodology

### **3. EXECUTIVE SUMMARY**

- 3.1 Vitiligo Drugs under active development, H1- 2019
- 3.2 Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
- 3.3 Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
- 3.4 Companies involved in Vitiligo pipeline, H1- 2019
- 3.5 Mechanism of Action wise Vitiligo Pipeline Candidates

### **4. ACLARIS THERAPEUTICS INC VITILIGO PIPELINE DETAILS**

- 4.1 Aclaris Therapeutics Inc Business Profile
- 4.2 Aclaris Therapeutics Inc Vitiligo Drug Details
  - 4.2.1 Drug Snapshot
    - 4.2.1.1 Originator
    - 4.2.1.2 Collaborator/Co-Developer
    - 4.2.1.3 Route of Administration
    - 4.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 4.2.1.5 Area
    - 4.2.1.6 Type of Molecular Entity
- 4.3 Current Status
- 4.4 Drug Overview
- 4.5 Drug Mechanism of Action
- 4.6 Clinical/Pre-clinical Trial Details
- 4.7 Latest Drug Developments

## **5. ARRIEN PHARMACEUTICALS LLC VITILIGO PIPELINE DETAILS**

- 5.1 Arrien Pharmaceuticals LLC Business Profile
- 5.2 Arrien Pharmaceuticals LLC Vitiligo Drug Details
  - 5.2.1 Drug Snapshot
    - 5.2.1.1 Originator
    - 5.2.1.2 Collaborator/Co-Developer
    - 5.2.1.3 Route of Administration
    - 5.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 5.2.1.5 Area
    - 5.2.1.6 Type of Molecular Entity
- 5.3 Current Status
- 5.4 Drug Overview
- 5.5 Drug Mechanism of Action
- 5.6 Clinical/Pre-clinical Trial Details
- 5.7 Latest Drug Developments

## **6. AXIM BIOTECHNOLOGIES INC VITILIGO PIPELINE DETAILS**

- 6.1 Axim Biotechnologies Inc Business Profile
- 6.2 Axim Biotechnologies Inc Vitiligo Drug Details
  - 6.2.1 Drug Snapshot
    - 6.2.1.1 Originator
    - 6.2.1.2 Collaborator/Co-Developer
    - 6.2.1.3 Route of Administration
    - 6.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 6.2.1.5 Area
    - 6.2.1.6 Type of Molecular Entity
- 6.3 Current Status
- 6.4 Drug Overview
- 6.5 Drug Mechanism of Action
- 6.6 Clinical/Pre-clinical Trial Details
- 6.7 Latest Drug Developments

## **7. BOSTON PHARMACEUTICALS INC VITILIGO PIPELINE DETAILS**

- 7.1 Boston Pharmaceuticals Inc Business Profile
- 7.2 Boston Pharmaceuticals Inc Vitiligo Drug Details
  - 7.2.1 Drug Snapshot

- 7.2.1.1 Originator
- 7.2.1.2 Collaborator/Co-Developer
- 7.2.1.3 Route of Administration
- 7.2.1.4 Orphan Drug/Fast Track/Special Designation
- 7.2.1.5 Area
- 7.2.1.6 Type of Molecular Entity
- 7.3 Current Status
- 7.4 Drug Overview
- 7.5 Drug Mechanism of Action
- 7.6 Clinical/Pre-clinical Trial Details
- 7.7 Latest Drug Developments

## **8. BRISTOL-MYERS SQUIBB CO VITILIGO PIPELINE DETAILS**

- 8.1 Bristol-Myers Squibb Co Business Profile
- 8.2 Bristol-Myers Squibb Co Vitiligo Drug Details
  - 8.2.1 Drug Snapshot
    - 8.2.1.1 Originator
    - 8.2.1.2 Collaborator/Co-Developer
    - 8.2.1.3 Route of Administration
    - 8.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 8.2.1.5 Area
    - 8.2.1.6 Type of Molecular Entity
- 8.3 Current Status
- 8.4 Drug Overview
- 8.5 Drug Mechanism of Action
- 8.6 Clinical/Pre-clinical Trial Details
- 8.7 Latest Drug Developments

## **9. CELGENE CORP VITILIGO PIPELINE DETAILS**

- 9.1 Celgene Corp Business Profile
- 9.2 Celgene Corp Vitiligo Drug Details
  - 9.2.1 Drug Snapshot
    - 9.2.1.1 Originator
    - 9.2.1.2 Collaborator/Co-Developer
    - 9.2.1.3 Route of Administration
    - 9.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 9.2.1.5 Area

- 9.2.1.6 Type of Molecular Entity
- 9.3 Current Status
- 9.4 Drug Overview
- 9.5 Drug Mechanism of Action
- 9.6 Clinical/Pre-clinical Trial Details
- 9.7 Latest Drug Developments

## **10. CLINUVEL PHARMACEUTICALS LTD VITILIGO PIPELINE DETAILS**

- 10.1 Clinuvel Pharmaceuticals Ltd Business Profile
- 10.2 Clinuvel Pharmaceuticals Ltd Vitiligo Drug Details
  - 10.2.1 Drug Snapshot
    - 10.2.1.1 Originator
    - 10.2.1.2 Collaborator/Co-Developer
    - 10.2.1.3 Route of Administration
    - 10.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 10.2.1.5 Area
    - 10.2.1.6 Type of Molecular Entity
- 10.3 Current Status
- 10.4 Drug Overview
- 10.5 Drug Mechanism of Action
- 10.6 Clinical/Pre-clinical Trial Details
- 10.7 Latest Drug Developments

## **11. INCYTE CORP VITILIGO PIPELINE DETAILS**

- 11.1 Incyte Corp Business Profile
- 11.2 Incyte Corp Vitiligo Drug Details
  - 11.2.1 Drug Snapshot
    - 11.2.1.1 Originator
    - 11.2.1.2 Collaborator/Co-Developer
    - 11.2.1.3 Route of Administration
    - 11.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 11.2.1.5 Area
    - 11.2.1.6 Type of Molecular Entity
- 11.3 Current Status
- 11.4 Drug Overview
- 11.5 Drug Mechanism of Action
- 11.6 Clinical/Pre-clinical Trial Details

11.7 Latest Drug Developments

## **12. JN BIOSCIENCES LLC VITILIGO PIPELINE DETAILS**

12.1 JN Biosciences LLC Business Profile

12.2 JN Biosciences LLC Vitiligo Drug Details

12.2.1 Drug Snapshot

12.2.1.1 Originator

12.2.1.2 Collaborator/Co-Developer

12.2.1.3 Route of Administration

12.2.1.4 Orphan Drug/Fast Track/Special Designation

12.2.1.5 Area

12.2.1.6 Type of Molecular Entity

12.3 Current Status

12.4 Drug Overview

12.5 Drug Mechanism of Action

12.6 Clinical/Pre-clinical Trial Details

12.7 Latest Drug Developments

## **13. PORTOLA PHARMACEUTICALS INC VITILIGO PIPELINE DETAILS**

13.1 Portola Pharmaceuticals Inc Business Profile

13.2 Portola Pharmaceuticals Inc Vitiligo Drug Details

13.2.1 Drug Snapshot

13.2.1.1 Originator

13.2.1.2 Collaborator/Co-Developer

13.2.1.3 Route of Administration

13.2.1.4 Orphan Drug/Fast Track/Special Designation

13.2.1.5 Area

13.2.1.6 Type of Molecular Entity

13.3 Current Status

13.4 Drug Overview

13.5 Drug Mechanism of Action

13.6 Clinical/Pre-clinical Trial Details

13.7 Latest Drug Developments

## **14. RHEOS MEDICINES INC VITILIGO PIPELINE DETAILS**

14.1 Rheos Medicines Inc Business Profile



- 14.2 Rheos Medicines Inc Vitiligo Drug Details
  - 14.2.1 Drug Snapshot
    - 14.2.1.1 Originator
    - 14.2.1.2 Collaborator/Co-Developer
    - 14.2.1.3 Route of Administration
    - 14.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 14.2.1.5 Area
    - 14.2.1.6 Type of Molecular Entity
- 14.3 Current Status
- 14.4 Drug Overview
- 14.5 Drug Mechanism of Action
- 14.6 Clinical/Pre-clinical Trial Details
- 14.7 Latest Drug Developments

## **15. LATEST VITILIGO DRUG PIPELINE DEVELOPMENTS, 2019**

## **16. APPENDIX**

- 16.1 About Us
- 16.2 Sources and Methodology
- 16.3 Contact Information

## I would like to order

Product name: 2019 Future of Vitiligo R&D Pipeline Drugs and Companies- Analysis of Global Vitiligo Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

Product link: <https://marketpublishers.com/r/2CD33C30E33EN.html>

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2CD33C30E33EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

